9/16
08:07 am
sln
Silence Therapeutics (NASDAQ:SLN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
Silence Therapeutics (NASDAQ:SLN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.